NetworkNewsBreaks

ThursdaySep 19, 2019 9:21 am

NetworkNewsBreaks – IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) (FRA: IB3) Secures DTC Eligibility for U.S. Markets

IONIC Brands (CSE: IONC) (OTC: IONKF) (FRA: IB3) on Wednesday announced that it has achieved eligibility by The Depository Trust Company (“DTC”) for its shares on the OTC Market in the United States. DTC, a subsidiary of the Depository Trust & Clearing Corporation (“DTCC”), manages the electronic clearing and settlement of publicly traded companies. This method accelerates the receipt of stock and cash, fast-tracks the settlement process for investors and brokers and cuts transactional costs for participating brokerage firms. DTC eligibility enables stock to be traded over a significantly broader selection of brokerage firms, as several firms require DTC eligibility…

Continue Reading

WednesdaySep 18, 2019 2:17 pm

NetworkNewsBreaks – HTC Extraction Systems (TSX.V: HTC) Securing Several Hemp Biomass Tolling Contracts

HTC Extraction Systems (TSX.V: HTC), a gas, liquids and biomass extractor and refiner, recently entered into a tolling agreement to process five million kilograms of hemp biomass. An article discussing the company reads, “HTC recently announced its entry into a hemp-biomass tolling agreement, which will involve the processing of hemp biomass for the 2019 crop year (http://nnw.fm/FE4Rs). The agreement covers 4,200–5,000 acres of hemp in Saskatchewan, utilizing five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process an estimated five million kilograms of hemp biomass to extract CBD full-spectrum oil (FSO). The company will be paid a ‘toll…

Continue Reading

WednesdaySep 18, 2019 2:11 pm

NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Developing Solutions to Meet Major Therapeutic Needs

Endonovo Therapeutics (OTCQB: ENDV) develops, manufactures and distributes innovative medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. An article discussing the company reads, “Dr. Peter Novak, who recently joined Endonovo’s scientific advisory board, said he believes that the company’s noninvasive Electroceutical® Therapy represents ‘a fascinating new frontier.’ Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist. . . . ‘Endonovo has assembled a pipeline that…

Continue Reading

WednesdaySep 18, 2019 10:29 am

NetworkNewsBreaks – Pressure BioSciences Inc. (PBIO) Featured on Stock Day with Everett Jolley to Discuss Advancements in Proprietary Platforms

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced that its President and CEO Richard T. Schumacher was recently featured on The Stock Day Podcast hosted by Everett Jolley. During the interview, Schumacher discussed PBIO and the company’s recent achievements. “A year ago, PBIO had one revenue-generating division. We now have three, each based on our proprietary PCT, BaroFold, or UST platforms,” PBIO President and CEO Richard T. Schumacher said in the podcast. “Our PCT platform supports our primary business, which…

Continue Reading

WednesdaySep 18, 2019 10:22 am

NetworkNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) CEO to Present Via Webcast at September 19 Singular Research Midwestern Values Conference

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will present, via webcast, at the Singular Research Midwestern Values Conference on September 19, 2019. Genprex Chairman and CEO Rodney Varner will lead the company's webcast presentation. The presentation is scheduled to begin at 4:00 PM Central Time, and interested parties may register for the webcast via the Singular Research website. To view the full press release, visit http://nnw.fm/IxlP7 About Genprex, Inc. Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial…

Continue Reading

WednesdaySep 18, 2019 10:02 am

NetworkNewsBreaks – Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) Releases of Q4 and 2019 Fiscal Year End Financial Results

Supreme Cannabis Company (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) on Tuesday announced the release of its financial and operating results for the fourth quarter and fiscal year ended June 30, 2019. Among the results, the company reported achievement of its first positive Adjusted EBITDA quarter of $3.2 million, a 90% increase in net revenue to $19 million in Q4 2019, up from $10 million in Q3 2019, as well as a 370% increase in fiscal total revenue to $41.8 million in 2019, up from $8.9 million in 2018. “We end fiscal 2019 as one of the few Canadian cannabis businesses…

Continue Reading

WednesdaySep 18, 2019 9:28 am

NetworkNewsBreaks – Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF) Completes Debt Transaction

Plus Products (CSE: PLUS) (OTCQX: PLPRF), a leading cannabis branded products company in California, this morning announced the completion of the debt transaction previously announced by Plus on September 11 concerning the issuance of units consisting of subordinate voting shares and warrants in exchange for the settlement of certain debt. In accordance with an escrow agreement ancillary to the debt transaction, 50% of the issued shares will be held in escrow until specific conditions detailed in the agreement are met. Per the previous announcement regarding the transaction, all securities issued are subject to a statutory four-month hold period. To view…

Continue Reading

TuesdaySep 17, 2019 3:35 pm

NetworkNewsBreaks – Plus Therapeutics, Inc. (NASDAQ: PSTV) Changes Name, Ticker Symbol; Details Reverse Stock Split

Plus Therapeutics, (NASDAQ: PSTV) announced that it has officially changed its name from Cytori Therapeutics, Inc. to Plus Therapeutics, Inc. The company’s ticker symbol for its common stock on the Nasdaq Capital Market changed from ‘CYTX’ to ‘PSTV’ and the ticker symbol for its Series S Warrants changed from ‘CYTXZ’ to ‘PSTVZ’. In the news release, Plus Therapeutics detailed its plans to make a 1-for-50 reverse stock split become effective on August 5, 2019, transforming every 50 shares of the company’s common stock into one issued and outstanding share without any change in the par value of the shares. Following…

Continue Reading

TuesdaySep 17, 2019 2:30 pm

NetworkNewsBreaks – Organigram Holdings Inc.’s (TSX: OGI) (NASDAQ: OGI) Noteworthy Corporate Governance, Financial Performance Drive Success

Organigram Holdings (TSX: OGI) (NASDAQ: OGI), the parent company of Organigram Inc., a leading licensed producer of cannabis, was recently highlighted in an article by Bloomberg titled, ‘Organigram a Canadian Pot Rarity After Four Profitable Quarters’ (http://nnw.fm/YXap1). An article further discussing the company reads, “Along with the company’s impressive corporate governance comes its equally notable — and consistent — financial performance. This is likely due to its team’s adherence to fiscal discipline, something that can be difficult to find in this industry. Bloomberg noted that, with four quarters of profitability under its belt, Organigram Holdings is ‘an anomaly in the Canadian…

Continue Reading

TuesdaySep 17, 2019 2:23 pm

NetworkNewsBreaks – GB Sciences, Inc. (GBLX) Sells 50% Ownership Stake in GB Sciences Louisiana, LLC

GB Sciences (OTCQB: GBLX) today announced that it has filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC. for $16 million. The stake will be bought by Wellcana Plus at a fee of $7 million in cash at closing, $1 million in cash within 60 days of closing, and the remaining $8 million as an earn out. The profitability of the Louisiana operations will determine the proceeds realized through the earn out as well as the timing of those proceeds. The sale enables GBLX to focus on attaining a DEA license, profitability and…

Continue Reading